Filter by Event: European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2016
WCK 4282 (Cefepime-Tazobactam) MIC Quality Control Ranges Using a Multi-Laboratory Study Design
WCK 4282 (Cefepime-Tazobactam) MIC Quality Control Ranges Using a Multi-Laboratory Study Design, Lead author: Ross JE, presented at 26th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 9-12, 2016, Amsterdam, Netherlands
In Vitro Activity of WCK 4282 (High-Dose Cefepime-Tazobactam) Against Resistant Subsets of Enterobacteriaceae Collected Worldwide (2014)
In Vitro Activity of WCK 4282 (High-Dose Cefepime-Tazobactam) Against Resistant Subsets of Enterobacteriaceae Collected Worldwide (2014), Lead author: Sader HS, presented at 26th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 9-12, 2016, Amsterdam, Netherlands
Antimicrobial Activity of WCK 4282 (High-Dose Cefepime-Tazobactam) Tested against Gram-negative Organisms from Medical Centers Located in Europe and the Asia-Pacific Region
Antimicrobial Activity of WCK 4282 (High-Dose Cefepime-Tazobactam) Tested against Gram-negative Organisms from Medical Centers Located in Europe and the Asia-Pacific Region, Lead author: Sader HS, presented at 26th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 9-12, 2016, Amsterdam, Netherlands
WCK4282 (High-Dose Cefepime-Tazobactam) Antimicrobial Activity against Gram-negative Organisms from United States and Latin America medical Centers (2014)
WCK4282 (High-Dose Cefepime-Tazobactam) Antimicrobial Activity against Gram-negative Organisms from United States and Latin America medical Centers (2014), Lead author: Sader HS, presented at 26th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 9-12, 2016, Amsterdam, Netherlands
Omadacycline Activity Tested Against European Bacterial Isolates from a Combined 2010-2011 Global Surveillance Program
Omadacycline Activity Tested Against European Bacterial Isolates from a Combined 2010-2011 Global Surveillance Program, Lead author: Flamm RK, presented at 26th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 9-12, 2016, Amsterdam, Netherlands
Delafloxacin activity tested against bacterial pathogens from 44 medical centres in Europe and Israel (2014)
Delafloxacin activity tested against bacterial pathogens from 44 medical centres in Europe and Israel (2014), Lead author: Flamm RK, presented at 26th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 9-12, 2016, Amsterdam, Netherlands
The Activity of Tedizolid against Gram-positive Pathogens Isolated from Patients in Medical Centres in Europe, Turkey and Israel: 2014 Surveillance
The Activity of Tedizolid against Gram-positive Pathogens Isolated from Patients in Medical Centres in Europe, Turkey and Israel: 2014 Surveillance, Lead author: Farrell DJ, presented at 26th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 9-12, 2016, Amsterdam, Netherlands
Activity of Linezolid when Tested Against Contemporary European Bacterial Clinical Isolates (2015)
Activity of Linezolid when Tested Against Contemporary European Bacterial Clinical Isolates (2015), Lead author: Flamm RK, presented at 26th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 9-12, 2016, Amsterdam, Netherlands
Analysis of the activity of telavancin tested against a global collection of Staphylococcus aureus clinical isolates responsible for documented hospital-acquired pneumonia (2014)
Analysis of the activity of telavancin tested against a global collection of Staphylococcus aureus clinical isolates responsible for documented hospital-acquired pneumonia (2014), Lead author: Mendes RE, presented at 26th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 9-12, 2016, Amsterdam, Netherlands
Antimicrobial Activity of Tigecycline and Cefoperazone/Sulbactam Tested against 14,850 Gram-negative Organisms from Europe and the Asia-Pacific Region (2013-2014)
Antimicrobial Activity of Tigecycline and Cefoperazone/Sulbactam Tested against 14,850 Gram-negative Organisms from Europe and the Asia-Pacific Region (2013-2014), Lead author: Sader HS, presented at 26th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 9-12, 2016, Amsterdam, Netherlands
Oritavancin activity tested against European staphylococcal clinical isolates and resistant subsets inlcuding those with reduced susceptibility to daptomycin, teicoplanin or vancomycin (2010-2014)
Oritavancin activity tested against European staphylococcal clinical isolates and resistant subsets inlcuding those with reduced susceptibility to daptomycin, teicoplanin or vancomycin (2010-2014), Lead author: Mendes RE, presented at 26th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 9-12, 2016, Amsterdam, Netherlands
ß-lactamase characterization of baseline Enterobacteriaceae from Phase 3 trials of ceftazidime-avibactam for the treatment of complicated urinary tract infections
ß-lactamase characterization of baseline Enterobacteriaceae from Phase 3 trials of ceftazidime-avibactam for the treatment of complicated urinary tract infections, Lead author: Mendes RE, presented at 26th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 9-12, 2016, Amsterdam, Netherlands
Activity of Ceftolozane/Tazobactam tested against Organisms from Urinary Tract Pathogens Collected from 41 Medical Centres in Europe, Turkey and Israel (2014)
Activity of Ceftolozane/Tazobactam tested against Organisms from Urinary Tract Pathogens Collected from 41 Medical Centres in Europe, Turkey and Israel (2014), Lead author: Farrell DJ, presented at 26th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 9-12, 2016, Amsterdam, Netherlands
Ceftolozane/Tazobactam Activity against Intra-Abdominal Pathogens Collected from 41 Medical Centres in Europe, Turkey and Israel (2014)
Ceftolozane/Tazobactam Activity against Intra-Abdominal Pathogens Collected from 41 Medical Centres in Europe, Turkey and Israel (2014), Lead author: Farrell DJ, presented at 26th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 9-12, 2016, Amsterdam, Netherlands
Antimicrobial Activity of Ceftolozane/Tazobactam from the PACTS Programme Tested against Enterobacteriaceae Isolated from Patients Hospitalised in Intensive Care Units from 19 European Countries, Turkey and Israel (2013-2014)
Antimicrobial Activity of Ceftolozane/Tazobactam from the PACTS Programme Tested against Enterobacteriaceae Isolated from Patients Hospitalised in Intensive Care Units from 19 European Countries, Turkey and Israel (2013-2014), Lead author: Farrell DJ, presented at 26th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 9-12, 2016, Amsterdam, Netherlands
Antimicrobial Activity of Ceftolozane/Tazobactam from the PACTS Programme Tested against Pseudomonas aeruginosa Isolated from Patients Hospitalised in Intensive Care Units in Europe, Turkey and Israel (2013-2014)
Antimicrobial Activity of Ceftolozane/Tazobactam from the PACTS Programme Tested against Pseudomonas aeruginosa Isolated from Patients Hospitalised in Intensive Care Units in Europe, Turkey and Israel (2013-2014), Lead author: Farrell DJ, presented at 26th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 9-12, 2016, Amsterdam, Netherlands
In Vitro Activity of Plazomicin tested against Contemporary Clinical Isolates Collected in Asia-Pacific, Europe and Latin America
In Vitro Activity of Plazomicin tested against Contemporary Clinical Isolates Collected in Asia-Pacific, Europe and Latin America, Lead author: Castanheira M, presented at 26th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 9-12, 2016, Amsterdam, Netherlands
